Bifogade filer
IRLAB granted additional patent for its drug candidate pirepemat expanding the patent protection in the US
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Gothenburg, Sweden, September 18, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that a new patent has been granted in the US covering a salt of the drug candidate pirepemat. The patent covers the active pharmaceutical ingredient used in the ongoing clinical development of pirepemat.
"The patent granted today is an important addition to IRLAB’s already strong patent portfolio for pirepemat. The patent portfolio allows for a potential market exclusivity reaching into the early 2040s in most of the key geographies. The granting of this new patent brings a substantial increase in commercial value of the pirepemat program, " said Kristina Torfgård, CEO of IRLAB.
Pirepemat has the potential to become the first treatment in a new class of drugs designed to reduce falls, and thus fall injuries, in people living with Parkinson’s disease. The latest patent, covering the salt of the drug used in the ongoing clinical development, has previously been granted in Europe, Japan and China, predicted to expire in 2038. With the awarded patent term adjustment (PTA) and potential grant of patent term extension (PTE), exclusivity in the US will reach into the early 2040s. Pirepemat has previously been granted composition of matter patents, providing pirepemat exclusivity in all the major markets such as China, Europe, Japan, and the US. Furthermore, a patent directed to the process for the preparation of pirepemat has recently been granted in the US.